An interventional study of SW as medical devices(comperator) to evaluate the retinal image of the patient's eye (to identify if the patient has DR or if the patient is healthy) . in Diabetes Mellitus, sponsored by Bonmedix Holding a.s.. Recruiting at 1 site in Czechia. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-06-21.
Sponsored by Bonmedix Holding a.s. · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 120 studies in Diabetes Mellitus with a site in Czechia — 8 open to participants now, 12 under way, 3 of them phase 3. Diabetes Mellitus · Czechia.
Among the 120 studies in Diabetes Mellitus with a site in Czechia, this one is the 30th largest by planned enrollment of the 108 interventional ones that give a count, is one of 6 that started in 2024, is one of 14 with no phase, reaches primary completion later than 0 of the 11 other live ones, and was the 113th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →8 of the 120 studies in Diabetes Mellitus with a site in Czechia are open now. Recruiting first, the newest first:
Institute for Clinical and Experimental Medicine · Sites in Czechia
Ages 18+
Lukas Vanek · Sites in Czechia
Women only
CSL Behring · Sites in Czechia, United States, Argentina and 32 more countries
Ages 18+
Pharming Technologies B.V. · Sites in Czechia, United States, Australia and 8 more countries
Ages 18+
Charles University, Czech Republic · Sites in Czechia
Ages 18+
A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
120 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 24 · Phase 3 65 · Phase 4 7
First in 1994; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 80 across 6,027 interventional studies indexed under Diabetes Mellitus.
Median enrollment 464 across the 108 interventional studies, 640 across the 12 observational. Of the 102 that completed or were terminated, 61 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
100 of 120 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Bonmedix Holding a.s. as lead sponsor.
Bonmedix Holding a.s. has 1 study filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
2 of the studies in Diabetes Mellitus with a site in Czechia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT05650229Pharming Technologies B.V.Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease | 2027-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 120 studies in Diabetes Mellitus with a site in Czechia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A prospective, comparative multicenter evaluation conducted to capture patients with diabetic retinopathy in general practitioners, using AI medical device
A prospective, comparative multicenter evaluation conducted to capture patients with diabetic retinopathy in general practitioners, using the SWaMD medical device and the SWaMD comparator, when evaluating the patients retinal image
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SW as medical devices(investigational device) to evaluate the retinal image of the patient's eye (to identify if the patient has DR or if the patient is healthy) .
Device: SW as medical devices(comperator) to evaluate the retinal image of the patient's eye (to identify if the patient has DR or if the patient is healthy) .
second AI medical device to evaluate the retinal image of the patient's eye. two AI as MD will be evaluating the retinal image
Sensitivity and specificity
The sensitivity and specificity will be calculated using the evaluation of independent masked expert (ophthalmologist) as gold standard.
Time frame: 3 months
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2024 (actual). Primary completion is estimated for Oct 2024, 4 months after the start.
Of 160 industry-sponsored interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's planned 4 months is below that.
Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.